antiagregação

Antiagregação plaquetária em pacientes no peri-operatório de cirurgias cardíacas e não-cardíacas.

Fundamentos: A gest&atilde;o otimizada da terapia antiplaquet&aacute;ria perioperat&oacute;ria para pacientes com stents coron&aacute;rios n&atilde;o foi completamente esclarecida. Os dados atualmente dispon&iacute;veis sobre a seguran&ccedil;a e efic&aacute;cia de diferentes regimes antiplaquet&aacute;rios entre os pacientes submetidos &agrave; cirurgia com stent t&ecirc;m resultados inconsistentes. Com isso, um consenso foi elaborado por v&aacute;rias sociedades nacionais na It&aacute;lia, incluindo a<a href="https://solaci.org/en/2015/06/24/congress-item-9121/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | MODEL U-SES: More Devices for High Risk of Bleeding and Short DAPT

Courtesy of SBHCI. This study tested the safety of dual antiplatelet therapy (DAPT) after only three months of bioresorbable polymer sirolimus DES implantation (Ultimaster). Secondary end point was following with P2Y12 inhibitor monotherapy after the first 3 months compared with aspirin.&nbsp; It included 1695 patients treated with sirolimus eluting Ultimaster receiving 3-month DAPT. After the<a href="https://solaci.org/en/2019/09/30/tct-2019-model-u-ses-a-single-arm-study-of-3-month-dapt-in-patients-at-high-bleeding-risk-treated-with-a-bioabsorbable-polymer-based-sirolimus-eluting-stent/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding

Courtesy of the SBHCI. This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer coating chromium platinum stent, basically the Synergy stent. Drug release and polymer degradation within four months facilitate endothelization and would allow a shorter DAPT. Presented during the scientific sessions of TCT 2019, this study included 2009 high<a href="https://solaci.org/en/2019/09/30/tct-2019-evolve-short-dapt-a-single-arm-study-of-3-month-dapt-in-patients-at-high-bleeding-risk-treated-with-a-bioabsorbable-polymer-based-everolimus-eluting-stent/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | IDEAL-LM: Bioabsorbable Polymer DES vs. Permanent Polymer DES for Left Main Stenosis

Courtesy of SBHCI. This study showed that using the everolimus eluting stent with bioabsorbable polymer Synergy followed by 4 months of dual antiplatelet therapy (DAPT) to treat left main stenosis (LMS) was safe and effective, compared against using the everolimus eluting stent with permanent polymer Xience followed by the conventional 12 months DAPT.&nbsp; This study<a href="https://solaci.org/en/2019/09/30/tct-2019-ideal-lm-a-randomized-trial-of-a-bioabsorbable-polymer-des-with-4-month-dapt-vs-a-durable-polymer-des-with-12-month-dapt-in-patients-with-left-main-coronary-artery-disease/" title="Read more" >...</a>

Top